Natriumoxybat Neuraxpharm (Sodium Oxybate)

Sodium Oxybate, the active ingredient in Natriumoxybat Neuraxpharm, is a GABA_B receptor agonist presented as an oral formulation for oral use. It is indicated for the treatment of narcolepsy with cataplexy in adult patients. GNH USA supplies Natriumoxybat Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium Oxybate acts on the central nervous system to improve sleep architecture in patients with narcolepsy. - Narcolepsy with cataplexy: reduces the frequency of cataplexy attacks and improves nighttime sleep quality. - Excessive daytime sleepiness associated with narcolepsy: helps maintain wakefulness during the day. - Disrupted nocturnal sleep in narcolepsy: promotes consolidated sleep periods at night.

Sodium Oxybate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient pain often occurring after dosing. - Dizziness: sensation of light‑headedness or unsteadiness. - Vomiting: occasional expulsion of stomach contents. - Insomnia: difficulty initiating or maintaining sleep. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing requiring medical attention. - Seizures: convulsive episodes that may be life‑threatening. - Severe hypotension: marked drop in blood pressure leading to fainting. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Confusion or hallucinations: altered mental status requiring evaluation.

Before initiating therapy with Sodium Oxybate, several safety considerations should be observed. - Avoid alcohol: concurrent use can potentiate central nervous system depression. - Monitor respiratory function: patients with sleep‑disordered breathing require close observation. - Adjust dose in renal impairment: reduced clearance may increase exposure. - Do not discontinue abruptly: tapering is recommended to avoid rebound symptoms. - Contraindicated in severe obstructive sleep apnea: risk of worsening breathing. - Store at room temperature: keep in the original container, protect from moisture and light.

Sodium Oxybate can interact with other substances that depress the central nervous system or alter its metabolism.

Major Interactions (Avoid): - Alcohol: additive sedative effect increasing risk of respiratory depression. - Opioids: synergistic CNS depression that may be life‑threatening. - Benzodiazepines: enhanced sedation and respiratory compromise. - Other GABA_B agonists: excessive inhibitory signaling. - CNS depressants (e.g., barbiturates, antihistamines): heightened sedation.

Moderate Interactions (Monitor Closely): - Antidepressants (especially SSRIs): may affect sleep patterns. - Antihypertensives: potential additive hypotensive effect. - Anticonvulsants: possible alteration of seizure threshold. - CYP enzyme modulators: may influence drug metabolism, requiring dose adjustment.